This was the stock's second consecutive day of losses.

Coral Gables, FL-based Catalyst Pharmaceuticals , Inc. (NASDAQ:CPRX), a $2.69 billion market cap biopharmaceutical company that has delivered an impressive 54% return to shareholders over the past ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most ...

Shares of Catalyst Pharmaceuticals Inc. CPRX rose 1.32% to $22.21 Monday, on what proved to be an all-around mixed trading ...

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) had its price target raised by HC Wainwright from $30.00 to $35.00 in a note issued to investors on Friday,Benzinga reports. The brokerage ...

CORAL GABLES, Fla. - Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), a pharmaceutical company demonstrating excellent financial ...

StockNews.com downgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) from a strong-buy rating to a buy rating in a research note issued to investors on Saturday. CPRX has been the ...

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living ...

For Full Prescribing and Safety Information for FIRDAPSE, please visit www.firdapse.com.

View Catalyst Pharmaceuticals, Inc. (CPRX) current and estimated P/E ratio data provided by Seeking Alpha.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...